Strategies to reduce the incidence of endometrial cancer in postmenopausal women

American Journal of Obstetrics and Gynecology

Volumn 177, Issue 5, 1997, Pages 1196-1207

  Gambrell R D , Jr ^a   Fylstra, D L ^a   Kreutner, K A ^a   Mixson, W T ^a   Nunley, W C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Endometrial cancer; Postmenopausal women

Indexed keywords

DIURETIC AGENT; LIPID; LIPOPROTEIN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; SUPPOSITORY BASE;

ADULT; AMENORRHEA; CANCER INCIDENCE; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DOSE RESPONSE; ENDOMETRIUM CANCER; FEMALE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYSTEROSCOPY; INTRAVAGINAL DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0030834522     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9378(97)70040-1     Document Type: Conference Paper

References (41)

1. SL Parker T Tong S Bolden PA Wingo Cancer statistics, 1996 CA Cancer J Clin 46 1996 5 27
2. BA Miller LAG Ries BF Handey CL Kosary LA Brinton ER Trimble SEER cancer statistics review: 1971-1991 1993 National Cancer Institute Bethesda (MD) NIH Publication No.: 94-2789
3. RD Gambrell Jr FM Massey TA Castaneda AJ Ugenas A Ricci JM Wright Use of the progestogen challenge test to reduce the risk of endometrial cancer Obstet Gynecol 55 1980 732 738
4. JH Hanna WK Brady JM Hill GL Phillips Jr Detection of postmenopausal women at risk for endometrial carcinoma by a progesterone challenge test Am J Obstet Gynecol 147 1983 872 875
5. MA El-Maraghy N El-Badawy GA Wafa N Bishai Progesterone challenge test in postmenopausal women at high risk Maturitas 19 1994 53 57
6. K Petranik WT Kable C Bewtra JC Gallagher Use of progestin challenge test in elderly women [abstract] Menopause: J North Am Menopause Soc 2 1995 278
7. JP Guerrieri JC Elkas JD. Nash Evaluating the endometrium in women on tamoxifen: a pilot study to compare a “gold standard” with an “old standard.” Menopause: J North Am Menopause Soc 4 1997 6 9
8. MK Toppozada AAA Ismail RSM Hamed KS Ahmed A El-Faras Progesterone challenge test and estrogen assays in menopausal women with endometrial adenomatous hyperplasia Int J Gynecol Obstet 26 1988 115 119
9. S Nakamura T Douchi T Oki H Ijuin S Yamamoto Y Nagata Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding Obstet Gynecol 87 1996 722 725
10. MI Whitehead D Fraser Controversies concerning the safety of estrogen replacement therapy Am J Obstet Gynecol 156 1987 1313 1322
11. MEL Paterson T Wade-Evans DW Sturdee MH Thom JWW Studd Endometrial disease after treatment with oestrogens and progestogens in the climacteric BMJ 280 1980 822 824
12. KF McGonigle BY Karlan DA Barbuto RS Leucer LD Lagasse HL Judd Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy Gynecol Oncol 55 1994 126 132
13. LF Voight NS Weiss J Chu JR Daling B McKnight G van Belle Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer Lancet 338 1991 274 277
14. AT Leather M Savvas JWW Studd Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women Obstet Gynecol 78 1991 1008 1010
15. L Goodman J Awwad K Marc I. Schiff Continuous combined hormonal replacement therapy and the risk of endometrial cancer—preliminary report Menopause: J North Am Menopause Soc 1 1994 57 59
16. RD Gambrell Jr PG. McDonough The “red queen” and endometrial hyperplasia [letter] Fertil Steril 61 1994 401 402
17. JT Comerci Jr AL Fields LD Runowicz GL Goldberg Continuous low dose combined hormone replacement therapy and the risk of endometrial cancer Gynecol Oncol 64 1997 425 430
18. M Doren HPG Schneider Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women Maturitas 25 1996 99 105
19. E Darj S Nilsson O Axelsson D Hellberg Clinical and endometrial effects of oestradiol and progesterone in postmenopausal women Maturitas 13 1991 109 115
20. A Cerin K Heldaas B Moeller Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy [letter] N Engl J Med 334 1996 668 669
21. CM Dollbaum G Duwe Absorption of progesterone after topical application: serum and saliva levels [abstract] Menopause: J North Am Menopause Soc 3 1996 241
22. RD Gambrell Jr A-Z Teran Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy Am J Obstet Gynecol 165 1991 307 317
23. Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women JAMA 273 1995 199 208
24. J Jensen L Nilas C Christiansen Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy Br J Obstet Gynaecol 93 1986 613 618
25. E Barrett-Connor DL Wingard MH Criqui Postmenopausal estrogen use and heart disease risk factors in the 1980s JAMA 261 1989 2095 2100
26. RD Gambrell Jr Management of hormone replacement therapy side effects Menopause: J North Am Menopause Soc 1 1994 67 72
27. MI Whitehead D Fraser The effects of estrogens and progestins on the endometrium Obstet Gynecol Clin North Am 14 1987 299 320
28. SL Parker T Tong S Bolden PA Wingo Cancer statistics, 1997 CA Cancer J Clin 47 1997 5 27
29. Cancer Steroid Hormone Study of the Centers for Disease Control the National Institute of Child Health Human Development Combination oral contraceptive use and the risk of endometrial cancer JAMA 257 1987 796 800
30. BS Hulka LE Chainbless DG Kaufman WC Fowler BG Greenberg Protection against endometrial carcinoma by combination-product oral contraceptives JAMA 247 1982 475 477
31. DW Kaufman S Shapiro D Slone L Rosenberg OS Miettinet PD Stolley Decreased risk of endometrial cancer among oral-contraceptive users N Engl J Med 303 1980 1045 1047
32. EA Lew L Garfinkel Variation in mortality by weight among 750,000 men and women J Chronic Dis 32 1979 563 576
33. PG Rose Endometrial carcinoma N Engl J Med 335 1996 640 649
34. S Shapiro JP Kelly L Rosenberg DW Kaufman SP Helmrich NB Rosenshein Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens N Engl J Med 313 1985 969 972
35. GL Rubin HB Peterson NC Lee EF Maes PA Wingo S Becket Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies Am J Obstet Gynecol 162 1990 148 154
36. LF Voigt NS Weiss J Chu JR Daling B McKnight G vanBelle Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer Lancet 338 1991 274 277
37. I Persson H Adami L Bergkvist A Lindgren B Pettersson R Hoover Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: result of a prospective study BMJ 298 1989 147 151
38. JT Chambers M Merino El Kohorn RE Peschel PE Schwartz Uterine serous papillary carcinoma Obstet Gynecol 67 1987 109 113
39. M Hendrickson J Ross P Eifel A Martinez R Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
40. RJ Kurman RE Scully Clear cell carcinoma of the endometrium: an analysis of 21 cases Cancer 37 1976 872 882
41. G Lane NC Siddle TA Ryder J Pryse-Davies RJB King MI Whitehead Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertil Steril 45 1986 345 352